CD8 antibody | YCATE55.9

100% Secure


Rat anti Dog CD8:Alexa Fluor® 647

Rat anti Dog CD8:FITC

Rat anti Dog CD8:Pacific Blue®

Rat anti Dog CD8

Rat anti Dog CD8:RPE

Rat anti Dog CD8:Alexa Fluor® 700

Product Type
Monoclonal Antibody
Clone
YCATE55.9
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA1039A647 F 100 Tests/1ml
MCA1039F F 0.1 mg
MCA1039PB F 100 Tests/1ml
MCA1039GA C F IF 0.1 mg
MCA1039PE F 100 Tests
MCA1039A700 F 100 Tests/1ml
Rat anti Dog CD8 antibody, clone YCATE55.9 was clustered as Canine CD8 in the First Canine Leukocyte Antigen Workshop (Cobbold et al. 1994). YCATE55.9 reacts with a rat cell line transfected with cDNA for canine CD8α (Gorman et al. 1994) and blocks MHC class I dependant T-cell responses in vitro and in vivo.

Rat anti Dog CD8, clone YCATE55.9 has been shown to deplete circulating CD8+ T cells when administered to dogs in vivo. (Watson et al. 1993) Reduced levels of circulating CD8+ T cells has been associated with decreased survival times for dogs with osteosarcoma (Biller et al. 2010)

Product Details

Target Species
Dog
Product Form
Purified IgG conjugated to Alexa Fluor® 647 - liquid
Product Form
Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Product Form
Purified IgG conjugated to Pacific Blue® - liquid
Product Form
Purified IgG - liquid
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Product Form
Purified IgG conjugated to Alexa Fluor® 700 - liquid
Reconstitution
Reconstitute with 1ml distilled water
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
5%Sucrose
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Carrier Free
Yes
Immunogen
Canine CD8 alpha chimaeric human IgG1 Fc fusion protein.
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Fusion Partners
Spleen cells from immunised DA rat were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of reconstitution.
Shelf Life
18 months from date of despatch.

More Information

UniProt
P33706 Related reagents
Entrez Gene
CD8A Related reagents
GO Terms
GO:0016021 integral to membrane
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Regulatory
For research purposes only

Applications of CD8 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/5
Flow Cytometry Neat 1/5
Flow Cytometry Neat
Flow Cytometry 1/50 1/100
Immunofluorescence
Immunohistology - Frozen
Flow Cytometry Neat
Flow Cytometry Neat 1/5
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1 x 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1 x 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) STAR131A 1 ml C E P WB
Goat anti Rat IgG:Biotin (Mouse Adsorbed) STAR131B 0.5 mg C E IF P WB
Rabbit F(ab')2 anti Rat IgG:Dylight®800 STAR16D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Rat IgG:FITC STAR17B 1 mg F
Rabbit F(ab')2 anti Rat IgG:HRP STAR21B 1 mg C E P RE
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) STAR69 0.5 ml F
Goat anti Rat IgG:DyLight®649 (Mouse Adsorbed) STAR71D649GA 0.1 mg F IF
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) STAR71D800GA 0.1 mg F IF WB
Goat anti Rat IgG:HRP (Mouse Adsorbed) STAR72 0.5 mg C E P
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) STAR73 0.5 ml F

Negative Isotype Controls Available

Description Product Code Pack Size Applications List Price Quantity
Rat IgG1 Negative Control:Alexa Fluor® 647 MCA6004A647 100 Tests/1ml F
Rat IgG1 Negative Control:FITC MCA6004F 0.1 mg F
Rat IgG1 Negative Control:Pacific Blue® MCA6004PB 100 Tests/1ml F
Rat IgG1 Negative Control MCA6004GA 0.1 mg F
Rat IgG1 Negative Control:RPE MCA6004PE 100 Tests F
Rat IgG1 Negative Control:Alexa Fluor® 700 MCA6004A700 100 Tests/1ml F

Application Based External Images

Flow Cytometry

Immunofluorescence

Product Specific References

References for CD8 antibody

  1. Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
    Tissue Antigens. 43 (3): 137-54.
  2. Gorman, S.D. et al. (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens.
    Tissue Antigens. 43 (3): 184-8.
  3. Watson, C.J. et al. (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
    Br J Surg. 80 (11): 1389-92.
  4. Papadogiannakis, E.I. et al. (2009) Determination of intracellular cytokines IFN-gamma and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture.
    Can J Vet Res. 73 (2): 137-43.
  5. Benyacoub, J. et al. (2003) Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs.
    J Nutr. 133: 1158-62.
  6. Bird, R.C. et al. (2010) An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine.
    Cancer Immunol Immunother. 60: 87-97.
  7. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies.
    Cell Immunol. 263: 88-98.
  8. Estrela-Lima, A. et al. (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.
    BMC Cancer. 10: 256.
  9. Huang, Y.C. et al. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells.
    J Leukoc Biol. 84: 1501-10.
  10. Kornegay, J.N. et al. (2010) Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.
    Mol Ther. 18: 1501-8.
  11. Pichavant, C. et al. (2010) Expression of dog microdystrophin in mouse and dog muscles by gene therapy.
    Mol Ther. 18: 1002-9.
  12. Pinheiro, D. et al (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.
    Immunology. 132: 111-22.
  13. Reis, A.B. et al. (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.
    Clin Exp Immunol. 146: 303-11.
  14. Figueiredo, M.M. et al. (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with Leishmania infantum.
    Infect Immun. 82: 3704-12.
  15. Costa-Pereira, C. et al. (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
    BMC Vet Res. 11 (1): 92.
  16. Schaut, R.G. et al. (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis.
    J Immunol. Apr 13. pii: 1502678. [Epub ahead of print]
  17. Tagawa, M. et al. (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma.
    PLoS One. 11 (2): e0150030.
  18. Riondato, F. et al. (2015) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large b-cell lymphoma.
    Cytometry B Clin Cytom. Dec 13. [Epub ahead of print]
  19. Cortese, L. et al. (2015) An immune-modulating diet increases the regulatory T cells and reduces T helper 1 inflammatory response in Leishmaniosis affected dogs treated with standard therapy.
    BMC Vet Res. 11: 295.
  20. Miller, J. et al. (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism.
    J Comp Pathol. 153 (1): 28-37.
  21. Riondato, F. et al. (2016) Identification of a suitable internal control for fluorescence analysis on canine peripheral blood samples.
    Vet Immunol Immunopathol. 172: 38-42.
  22. Martini, V. et al. (2015) Canine small clear cell/T-zone lymphoma: clinical presentation and outcome in a retrospective case series.
    Vet Comp Oncol. Jun 3. [Epub ahead of print]
  23. Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
    Vet Immunol Immunopathol. 159 (1-2): 91-6.
  24. Duz AL et al. (2014) The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs.
    Mem Inst Oswaldo Cruz. 109 (8): 1005-13.
  25. Munhoz, T.D. et al. (2016) Regulatory T cells in dogs with multicentric lymphoma: peripheral blood quantification at diagnosis and after initial stage chemotherapy
    Arq. Bras. Med. Vet. Zootec., v.68, n.1, p.1-9, 2016
  26. Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
    Immunobiology. 221 (1): 12-22.
  27. Viana, K.F. et al. (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with Leishmania chagasi.
    Vet Parasitol. 211 (3-4): 124-32.
  28. Bromberek, J.L. et al. (2016) Breed Distribution and Clinical Characteristics of B Cell Chronic Lymphocytic Leukemia in Dogs.
    J Vet Intern Med. 30 (1): 215-22.
  29. Mie K et al. (2016) Influence of transfusion of lymphokine-activated T killer cells on inflammatory responses in dogs after laparotomy.
    J Vet Med Sci. Jan 2. [Epub ahead of print]
  30. Miglio, A. et al. (2014) Acute undifferentiated leukaemia in a dog.
    Aust Vet J. 92 (12): 499-503.
  31. Villaescusa, A. et al. (2015) Effects of doxycycline on haematology, blood chemistry and peripheral blood lymphocyte subsets of healthy dogs and dogs naturally infected with Ehrlichia canis.
    Vet J. 204 (3): 263-8.
  32. Fiuza JA et al. (2015) Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Vaccine. 33 (2): 280-8.
  33. Perosso, J. et al. (2014) Alteration of sFAS and sFAS ligand expression during canine visceral leishmaniosis.
    Vet Parasitol. 205 (3-4): 417-23.
  34. Heinrich, F. et al. (2015) Immunophenotyping of immune cell populations in the raccoon (Procyon lotor).
    Vet Immunol Immunopathol. 168 (3-4): 140-6.
  35. Poggi A et al. (2016) Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
    Vet Comp Oncol. Jan 21. [Epub ahead of print]
  36. McGill, J.L. et al. (2016) Vaccination with an Attenuated Mutant of Ehrlichia chaffeensis Induces Pathogen-Specific CD4+ T Cell Immunity and Protection from Tick-Transmitted Wild-Type Challenge in the Canine Host.
    PLoS One. 11 (2): e0148229.
  37. Villaescusa, A. et al. (2012) Evaluation of peripheral blood lymphocyte subsets in family-owned dogs naturally infected by Ehrlichia canis.
    Comp Immunol Microbiol Infect Dis. 35 (4): 391-6.
  38. Schaut RG et al. (2016) Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Vaccine. 34 (44): 5225-5234.
  39. Miranda, S. et al. (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
    Vet Parasitol. 144 (3-4): 251-60.
  40. Viana, K.F. et al. (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
    Parasit Vectors. 9: 250.
  41. Michael, H.T. et al. (2013) Isolation and characterization of canine natural killer cells.
    Vet Immunol Immunopathol. 155 (3): 211-7.
  42. Mitchell, L. et al. (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma.
    Vet Immunol Immunopathol. 145 (3-4): 597-603.
  43. DaSilva, A.V.A. et al. (2018) Morphophysiological changes in the splenic extracellular matrix of Leishmania infantum-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens.
    PLoS Negl Trop Dis. 12 (4): e0006445.